Marker Therapeutics Inc
NASDAQ:MRKR

Watchlist Manager
Marker Therapeutics Inc Logo
Marker Therapeutics Inc
NASDAQ:MRKR
Watchlist
Price: 1.54 USD 3.36% Market Closed
Market Cap: 25.7m USD

MRKR's latest stock split occurred on Jan 27, 2023

The company executed a 1-for-10 stock split, meaning that for every 10 shares held, investors received 1 new share.

Before the split, MRKR traded at 0.3528 per share. Afterward, the share price was about 3.117.

The adjusted shares began trading on Jan 27, 2023. This was MRKR's 6th stock split, following the previous one in Sep 16, 2016.

Last Splits:
Jan 27, 2023
1-for-10
Sep 16, 2016
1-for-12
Feb 25, 2014
1-for-100
Jul 27, 2009
1-for-10
Jun 28, 2007
10-for-25
Pre-Split Price
3.528 0.3528
Post-Split Price
3.117
Before
After
Last Splits:
Jan 27, 2023
1-for-10
Sep 16, 2016
1-for-12
Feb 25, 2014
1-for-100
Jul 27, 2009
1-for-10
Jun 28, 2007
10-for-25

Marker Therapeutics Inc
Stock Splits History

MRKR Stock Splits Timeline
Jan 27, 2023
Jan 27, 2023
Split 1-for-10
/0.1
Pre-Split Price
3.528 0.3528
Post-Split Price
3.117
Before
After
Sep 16, 2016
Sep 16, 2016
Split 1-for-12
/0.083333333333333
Pre-Split Price
51.6 0.43
Post-Split Price
55.5
Before
After
Feb 25, 2014
Feb 25, 2014
Split 1-for-100
/0.01
Pre-Split Price
347.9999 0.029
Post-Split Price
371.9998
Before
After
Jul 27, 2009
Jul 27, 2009
Split 1-for-10
/0.1
Pre-Split Price
19 800 0.165
Post-Split Price
31 199.988
Before
After
Jun 28, 2007
Jun 28, 2007
Split 10-for-25
/0.4
Pre-Split Price
35 999.97 0.12
Post-Split Price
46 799.976
Before
After
Jun 8, 2001
Jun 8, 2001
Split 1-for-50
/0.02
Pre-Split Price
N/A
Post-Split Price
317 999.7
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Jan 20, 2026
Linius Technologies Ltd
OTC:LNNTF
1-for-100
/100
0.0001 0.0001 USD N/A
Jan 20, 2026
Lotus Resources Ltd
OTC:LTSRF
1-for-11
/11
0.13 0.13 USD N/A
Jan 15, 2026
Amcor PLC
NYSE:AMCR
1-for-5
/5
8.41 8.41 USD N/A
Jan 8, 2026
Sumitomo Realty & Development Co Ltd
OTC:SURYY
2-for-1
x2
25.635 25.635 USD N/A
Dec 30, 2025
Adicet Bio Inc
NASDAQ:ACET
1-for-16
/16
0.4921 0.4921 USD 7.93 7.93 USD
Load More

Marker Therapeutics Inc
Glance View

Market Cap
25.7m USD
Industry
Biotechnology

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company is headquartered in Houston, Texas and currently employs 56 full-time employees. The company went IPO on 2016-11-08. The firm specializes in the development and commercialization of T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The firm has developed its lead product candidates from its MultiTAA-specific T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (TAAs), which are tumor targets, and then kill tumor cells expressing those targets. The company has three MultiTAA-specific T cell therapies through clinical development, which include Autologous MultiTAA-specific T cell therapies, Allogeneic MultiTAA-specific T cell therapies and Off-the-shelf MultiTAA-specific T cell therapies. The firm is focused on developing MT-601 for the treatment of advanced unresectable pancreatic cancer.

MRKR Intrinsic Value
Not Available
Back to Top